Financial Data and Key Metrics Changes - In Q3 2025, revenue grew by 54% compared to Q3 2024, driven by key products [6][9] - Gross margin as a percentage of revenue was 83.6%, an increase of 1.4 percentage points year-over-year [9] - Earnings per share increased to $7.02, compared to $1.18 in Q3 2024 [10] Business Line Data and Key Metrics Changes - Revenue from key products accounted for $12 billion in the quarter, with significant contributions from immunology, oncology, and cardiometabolic health [11][12] - EBGLYSS prescriptions increased by 41% in Q3 2025 compared to Q2 2025 [11] - Mounjaro's total prescriptions grew by over 60% in the U.S. [14] Market Data and Key Metrics Changes - U.S. revenue increased by 45%, with strong volume growth from Zepbound and Mounjaro, despite a 15% decline in price [10] - International revenue increased by over 100% in constant currency, reflecting strong uptake of Mounjaro [10] - Japan, China, and the rest of the world saw constant currency revenue growth of 24%, 22%, and 51%, respectively [10] Company Strategy and Development Direction - The company is focused on expanding its manufacturing footprint and has announced plans for new facilities in the U.S. [7][8] - Lilly aims to leverage its robust pipeline and R&D investments to maintain a competitive edge in the market [51][53] - The company is pursuing an "all of the above" strategy to expedite the launch of orforglipron [39] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong performance and market share gains in the incretin analogs market [6][9] - The company raised its revenue and earnings per share guidance for the year based on strong financial performance [6][15] - Management acknowledged the competitive landscape but emphasized confidence in their portfolio and execution strategy [51][53] Other Important Information - The company distributed $1.3 billion in dividends and executed approximately $700 million in share repurchases during the quarter [8] - Lilly achieved several key milestones, including FDA approvals and positive trial results for multiple products [7][26] Q&A Session Summary Question: Comments on orforglipron and its market launch - Management indicated a focus on getting orforglipron to patients quickly and is pursuing various strategies to expedite its launch [39] Question: Insights on Mounjaro's international ramp - Management noted strong performance in new markets and emphasized the importance of patient activation for obesity treatment [46] Question: Market dynamics and competitor behavior - Management expressed confidence in their competitive position and highlighted ongoing investments in R&D and execution [51][53] Question: Pricing and volume dynamics for orforglipron - Management discussed the importance of understanding price elasticity and the potential for significant market expansion with orforglipron [85]

Financial Data and Key Metrics Changes - In Q3 2025, revenue grew by 54% compared to Q3 2024, driven by key products [4][9] - Gross margin as a percentage of revenue was 83.6%, an increase of 1.4 percentage points year-over-year [9] - Earnings per share increased to $7.02, compared to $1.18 in Q3 2024 [10] Business Line Data and Key Metrics Changes - Revenue from key products accounted for $12 billion in the quarter, with significant growth in immunology, oncology, and cardiometabolic health [11][12] - EVGLIS prescriptions increased by 41% in the U.S. for atopic dermatitis [11] - Mounjaro's total prescriptions grew by over 60% in the U.S. [14] Market Data and Key Metrics Changes - U.S. revenue increased by 45%, driven by strong volume growth of Zepbound and Mounjaro, despite a 15% decline in price [10] - International revenue increased by over 100% in constant currency, reflecting strong uptake of Mounjaro [10] - Japan, China, and the rest of the world saw constant currency revenue growth of 24%, 22%, and 51%, respectively [10] Company Strategy and Development Direction - The company is focused on expanding its manufacturing footprint and has announced plans for new facilities in the U.S. [6][7] - The strategy includes pursuing multiple pathways to market for Orforglipron, aiming for rapid patient access [43] - The company is committed to innovation and execution, with a robust pipeline and ongoing investments in R&D [60][62] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strong performance and market share gains, particularly in the incretin analogs market [4][9] - The company raised its revenue and earnings per share guidance for the year, anticipating full-year revenue between $63 billion and $63.5 billion [16] - Management highlighted the importance of transparency in pricing and the potential impact of recent changes in PBM models on market dynamics [73] Other Important Information - The company distributed $1.3 billion in dividends and executed approximately $700 million in share repurchases during the quarter [8] - Significant progress was made in R&D, with multiple positive Phase 3 trial results announced [17][20] Q&A Session Summary Question: Comments on Orforglipron and National Priority Review voucher program - Management indicated interest in getting Orforglipron to patients quickly and is pursuing various strategies for market entry [43] Question: Insights on Mounjaro's international ramp - Management noted strong performance in new markets and emphasized the importance of patient activation for obesity treatment [52] Question: Market dynamics and competitor behavior - Management expressed confidence in their competitive position and highlighted ongoing investments in R&D to maintain leadership [60][62] Question: Pricing and volume dynamics for Orforglipron - Management discussed the importance of direct-to-consumer platforms and the potential for significant market expansion with Orforglipron [115]

Core Insights - The market for obesity and diabetes treatments is experiencing significant growth, with Eli Lilly's drugs Mounjaro and Zepbound generating over $10 billion in sales during Q3, accounting for more than half of the company's total sales of $17.6 billion [1][5] - Novo Nordisk is pursuing the acquisition of Metsera Inc. for up to $9 billion, following Pfizer's nearly $5 billion bid for the same company, which is developing potential treatments but currently has no products on the market [2][6] - The popularity of GLP-1 receptor agonists is driving sales and acquisition interest, as they help regulate appetite and feelings of fullness, although they may not be effective for everyone and can cause side effects [3] Company Performance - Eli Lilly's Zepbound sales nearly tripled to $3.57 billion in Q3, while Mounjaro's revenue doubled to $6.52 billion, largely due to growth outside the U.S. [4] - Combined sales of Mounjaro and Zepbound have reached nearly $25 billion in 2023, surpassing Eli Lilly's total revenue for 2020, and contributing to a Q3 profit of $5.58 billion [5] Market Dynamics - Improved drug supplies and increasing insurance coverage are enhancing access to these treatments, which can cost around $500 per month without insurance [4] - Novo Nordisk's offer for Metsera includes a base payment of $56.50 per share, with potential additional payments based on drug development milestones, significantly increasing the value compared to previous trading prices [6] - Pfizer, known for its COVID-19 vaccine, is re-entering the obesity treatment space after previously halting its own drug development efforts [7]

Key Products & Market Performance - Tzepide and Mjaro (Zepbound) achieved market leadership in the US for both diabetes and obesity, driven by strong international performance [2] - Mangaro rollout in China, Brazil, and India indicates strong global demand [3] - Oral pill orforglipron is completing Phase 3 program with submission in Q4, aiming for broad global rollout [4][6] Pipeline & Clinical Trials - Oral pill offers a less intrusive alternative to injections, potentially appealing to those reaching their weight target [8] - Retatrutide, a triple-acting agent, shows promise for even greater weight loss than Zepbound or Mounjaro, with initial study focused on knee pain [10] - Studies are exploring the effects of weight loss drugs on inflammation, chronic knee pain, and addictive properties in the brain [11][12] Strategic Outlook - The company anticipates continued FDA approvals, supported by user fees, despite potential government shutdowns [7] - The company has built a head inventory to introduce orforglipron around the world [8] - The company is exploring additional indications beyond weight loss, such as knee pain and back pain, targeting a larger patient population [9][10]

Core Insights - The company reported a strong performance in Q3, leading to a significant guidance raise, indicating positive market conditions and operational success [1][4]. Product Performance - Tzepide and Mjaro Zepbound are key products, gaining market share in the rapidly growing diabetes and obesity sectors in the US, with strong international performance contributing to upside results [2]. - The global rollout of Mangaro in markets such as China, Brazil, and India has shown promising demand, although it is still in early stages [3]. Pipeline Developments - The company is advancing its product pipeline, with the oral pill orforron completing its phase three program and expected to submit for approval in Q4, alongside the approval of another cancer medication [4]. - The introduction of the oral solid formulation is seen as a significant addition to the product lineup, addressing the challenges of needle-based injections and catering to markets with limited refrigeration capabilities [8]. Future Growth Opportunities - The company is exploring additional indications for its weight loss drugs, including trials for knee and back pain, which could potentially address a large patient population in the US [9][10]. - There is ongoing research into the broader health benefits of these medications, including their effects on inflammation and other health conditions, which could open new avenues for growth [11][12].

Core Insights - Eli Lilly and Co. reported better-than-expected third-quarter earnings, leading to an increase in stock price and an upward revision of its annual forecast [1][8] Financial Performance - Quarterly revenue reached $17.60 billion, a 54% year-over-year increase, surpassing the consensus estimate of $16.02 billion, driven by a 62% increase in volume, partially offset by a 10% decrease due to lower realized prices [2] - Adjusted earnings per share were reported at $7.02, significantly up from $1.18 a year ago, exceeding the consensus of $5.70 [3] - Key Products revenue grew to $11.98 billion in Q3 2025, primarily driven by Mounjaro and Zepbound [2] Product Performance - Mounjaro's revenue increased by 109% to $6.52 billion, with U.S. revenue at $3.55 billion, reflecting a 49% increase [4] - Zepbound revenue surged 184% to $3.57 billion, driven by increased demand [5] - Verzenio revenue rose 7% to $1.47 billion, supported by volume growth [5] Profitability Metrics - Gross profit increased by 57% to $14.59 billion, with a gross margin of 82.9%, up by 1.9 percentage points due to a favorable product mix [5] Future Outlook - The company raised its fiscal year 2025 sales guidance from $60 billion-$62 billion to $63 billion-$63.5 billion, compared to the consensus of $61.65 billion [6] - Adjusted earnings guidance for 2025 was increased from $21.75-$23.00 to $23-$23.70, against a consensus of $22.18 [6] Investment and Expansion Plans - Eli Lilly announced a planned investment of over $1.2 billion to expand and modernize its manufacturing site in Puerto Rico, with construction expected to begin in 2026 [6][7] - The new facility will integrate advanced technologies and expand production capacity for oral solid medicines, including orforglipron, Lilly's first oral weight loss drug [7] - The project is expected to create up to 1,000 construction jobs and 100 high-tech manufacturing positions [8]

Core Insights - Eli Lilly reported adjusted earnings of $7.02 per share on $17.6 billion in third-quarter sales, exceeding analyst expectations of $5.89 per share and $16.05 billion in sales [1][2] - The company experienced significant growth in sales for its diabetes treatment Mounjaro, which generated $6.52 billion, and Zepbound, a weight-loss drug, which brought in $3.59 billion, both surpassing analyst projections [2] - Eli Lilly raised its full-year guidance, now expecting adjusted earnings of $23-$23.70 per share on sales of $63 billion-$63.5 billion, compared to the Street's expectations of $22.48 earnings per share and $61.74 billion in sales [2] Stock Performance - Eli Lilly's stock rose 3.9% to 845 in premarket trading, with a short-term high of 864.35 identified as a potential entry point for investors [3] - The stock is currently trading above key moving averages, although it has a low IBD Digital Relative Strength Rating of 33, indicating it ranks in the bottom third of stocks based on 12-month performance [3]

Financial Performance - Total revenue reached $17601 million, a 54% increase compared to Q3 2024[12, 17] - Key product revenue grew by 104%, reaching $12 billion[12] - Non-GAAP earnings per share (EPS) increased by $584 to $702[12] - The company raised the midpoint of full-year revenue guidance by over $2 billion[10] Product Highlights - Lilly's U S incretin analogs market share increased to 579% of total prescriptions, with market growth of 36% versus prior year[10, 26] - Mounjaro U S sales were $36 billion, and international sales were $30 billion[56] - Zepbound U S sales were $36 billion, and international sales were $20 million[59] - Verzenio U S sales were $880 million, and international sales were $590 million[62] - Jaypirca Q3 2025 sales were $143 million, with U S TRx increasing 61% vs Q3 2024[24] - Ebglyss Q3 2025 sales were $127 million, with U S TRx growing 41% vs Q2 2025[24] - Omvoh Q3 2025 sales were $65 million[24] - Kisunla Q3 2025 sales were $70 million[24] Strategic Investments - Year-to-date capital investments totaled $53 billion[12] - Research & Development investment was $35 billion, representing 27% of revenue[12] - Marketing, selling & administrative expenses were $27 billion, a 31% increase[12] - $13 billion was distributed via dividends and $07 billion in share repurchases[14] Regulatory and Clinical Updates - Inluriyo (imlunestrant) received U S FDA approval for ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer[11] - Kisunla received marketing authorization in Europe for early symptomatic Alzheimer's disease[11] - Orforglipron showed positive results in four additional Phase 3 trials[11] - Jaypirca significantly improved progression-free survival in treatment-naïve CLL/SLL[11]

Starbucks - Starbucks reported a mixed earnings report, with shares down 2% in pre-market trading despite achieving its first same-store sales gain in nearly two years, up 1% globally, driven by new protein drinks and improved morning staffing [2][3] - U.S. sales remained flat, while international sales increased by 3%, reflecting a 2% increase in China [2] - Revenue reached $9.57 billion, surpassing expectations of $9.33 billion, but adjusted EPS fell short at 52 cents compared to the expected 55 cents [3] - The CEO described the results as a turning point in Starbucks' multi-year turnaround, but the lack of a full outlook raised concerns among investors, with guidance expected in January [3][4] Eli Lilly - Eli Lilly experienced strong performance driven by its weight loss and diabetes drugs, with adjusted EPS at $7.02, beating expectations of $6.02 [4] - Revenue was reported at $17.6 billion, exceeding the anticipated figure of over $16 billion, and the company raised its full-year guidance to between $63 billion and $63.5 billion, up from a previous forecast of $60 to $62 billion [5][6] - Mjaro revenue more than doubled to over $6.5 billion, while Zetbound revenue almost tripled to over $3.12 billion, indicating strong demand for GLP-1 drugs [5][6] - Eli Lilly is also developing a new weight loss pill, which could potentially be a game changer in the market [7] Estee Lauder - Estee Lauder reported a return to profitability, beating expectations on both revenue and adjusted EPS, with revenue at $3.4 billion and adjusted EPS at 32 cents [8][10] - The company reaffirmed its full-year sales outlook and emphasized that fiscal year 2026 will be pivotal for restoring growth and expanding margins after four years of compression [9][10] - Growth was driven by skincare, which increased by 3%, and fragrance, which saw a significant rise of 14%, while makeup and hair care experienced declines of 1% and 7%, respectively [10][11] - Estee Lauder regained market share in China and the broader Asia-Pacific region, indicating a recovery in those markets [11]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The news team covers key finance and investing hubs including London, New York, Toronto, Vancouver, Sydney, and Perth [2] - Proactive focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [2][3] Group 2 - The team delivers insights across various sectors including biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto, and emerging digital and EV technologies [3] - Proactive adopts technology to enhance workflows and improve content production [4][5] - All content published by Proactive is edited and authored by humans, ensuring adherence to best practices in content production and search engine optimization [5]